Streetwise Reports' Article Archives — Current Month (1)

US Biotech Co. Targets Muscuar Dystrophy with First-In-Class Drug (06/01/2026)

Capricor Therapeutics Inc.'s (CAPR:NASDAQ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60.

more>

More Archives

2026May Apr Mar Feb Jan

2025Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec